Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Today, AbbVie's stock sits roughly 20% off its highs. It's a good time to take a breather, assess the underlying business, and consider whether the stock's decline offers enough value to make ...

AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 10 years ago, it would be worth $300.66 today based on a ...

Over the last five years, AbbVie's stock has experienced a negative price reaction on the day following its earnings announcement in 57% of cases. The median negative return during these instances ...

The analyst continues to be positive on AbbVie, as he maintained his outperform (buy, in other words) recommendation on the stock and $215 per-share price target. Not surprisingly, according to ...